ClinicalTrials.gg
RecruitingNCT07766018Updated Nov 5, 2026

A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer

A Phase 2 interventional study of Elacestrant in Breast Cancer, sponsored by Stemline Therapeutics, Inc.. Recruiting at 26 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Stemline Therapeutics, Inc. (part of Menarini Group) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 5, 202615 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing elacestrant in Breast Neoplasms — 15 open to participants now, 18 under way, 3 of them phase 3. elacestrant · Breast Neoplasms.

Planned enrollment
13th of 24
70 · median 72
Started
2026
with 5 others
Phase 2
11 of 24
10 open now
Primary completion
2028-10
later than 9 of 17 live
Registered
24th of 24
by date
Lead sponsor
9 of 24
Stemline Therapeutics, Inc.

Among the 24 studies testing elacestrant in Breast Neoplasms, this one is the 13th largest by planned enrollment, is one of 6 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 9 of the 17 other live ones, and was the 24th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 24 studies testing elacestrant in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About elacestrant

elacestrant: first FDA approval 2023 (ORSERDU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing elacestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter, open-label, Phase 2 bridging study to evaluate the efficacy and safety of elacestrant in Japanese post-menopausal women and men with estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer with estrogen receptor 1 gene mutation (ESR1-mut) whose disease has relapsed or progressed on at least 1 and no more than 2 prior lines of endocrine therapy for metastatic breast cancer, which must have included cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in combination with fulvestrant or an aromatase inhibitor.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Elacestrant
  • Bridging Study
  • Japan
  • ESR1-mutation
  • Breast Cancer
  • CDK4/6i
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have a or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of either locally advanced disease not amenable to resection or radiation therapy with curative intent or disease not amenable to curative therapy
  • Female participants must be (as defined by the protocol)
  • Must have ER+ and - tumor status confirmed per local laboratory testing
  • Participants must be ESR1-mutant positive determined via testing with the Guardant360 Companion Diagnostic panel test prior to enrollment
  • Must have disease progression during or within 28 days of completion of prior treatment with a CDK4/6 inhibitor in combination with either fulvestrant or an aromatase inhibitor (this counts as a line of prior endocrine therapy) for metastatic breast cancer

Key Exclusion Criteria:

  • Prior treatment with: elacestrant or or approved selective estrogen receptor degrader or ER antagonist; antibody-drug conjugate therapy for advanced/metastatic breast cancer; anti-cancer or investigational drug treatment
  • Radiation therapy within 14 days (28 days for brain lesions) before the first dose of study drug
  • Intact uterus with a history of endometrial intraepithelial neoplasia (atypical endometrial hyperplasia or higher-grade lesion)
  • Diagnosis of any other within 5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or second primary breast cancer

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Elacestrant

    Participants will receive elacestrant once daily.

    Drug: Elacestrant

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival as Assessed by the Imaging Review Committee

    Time frame: Up to approximately 27 months

Secondary outcomes

  1. Number of Participants with Adverse Events

    Time frame: Up to approximately 27 months

  2. Plasma Concentration of Elacestrant

    Time frame: Up to approximately 27 months

  3. Progression-free Survival as Assessed by the Investigator

    Time frame: Up to approximately 27 months

  4. Overall Survival

    Time frame: Up to approximately 27 months

07

Study locations

26 of 26 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2028, 26 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 26 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Aug 14, 2026
StartActual
Aug 18, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
15 sites added
Show 15 added (15 Japan)
  • Nagoya City University Hospital · Nagoya, Japan
  • National Hospital Organization - Nagoya Medical Center · Nagoya, Japan
  • Kindai University Hospital · Sakaishi, Japan
  • Hokkaido University Hospital · Sapporo, Japan
  • Shizuoka General Hospital · Shizuoka, Japan
  • Osaka University Hospital · Suita, Japan
  • Tokyo Medical University Hospital · Tokyo, Japan
  • Mie University Hospital · Tsu, Japan
  • Kansai Medical University Hospital · Hirakata, Japan
  • Hiroshima University Hospital · Hiroshima, Japan
  • Social medical corporation Hakuaikai - Sagara Hospital · Kagoshima, Japan
  • Jichi Medical University Hospital · Shimotsuke, Japan
  • Saint Luke's International Hospital · Tokyo, Japan
  • University of Tsukuba Hospital · Tsukuba, Japan
  • Kanagawa Cancer Center · Yokohama, Japan
across 2 updates, Oct 13, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    7 sites added
    Show 7 added (7 Japan)
    • Kansai Medical University Hospital · Hirakata, Japan
    • Hiroshima University Hospital · Hiroshima, Japan
    • Social medical corporation Hakuaikai - Sagara Hospital · Kagoshima, Japan
    • Jichi Medical University Hospital · Shimotsuke, Japan
    • Saint Luke's International Hospital · Tokyo, Japan
    • University of Tsukuba Hospital · Tsukuba, Japan
    • Kanagawa Cancer Center · Yokohama, Japan
    + 1 other change: verification date
  2. Oct 13, 2026
    8 sites added
    Show 8 added (8 Japan)
    • Nagoya City University Hospital · Nagoya, Japan
    • National Hospital Organization - Nagoya Medical Center · Nagoya, Japan
    • Kindai University Hospital · Sakaishi, Japan
    • Hokkaido University Hospital · Sapporo, Japan
    • Shizuoka General Hospital · Shizuoka, Japan
    • Osaka University Hospital · Suita, Japan
    • Tokyo Medical University Hospital · Tokyo, Japan
    • Mie University Hospital · Tsu, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07766018
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Aug 18, 2026
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Stemline Trials
Contact
clinicaltrials@menarinistemline.com
1-877-332-7961
Medical Director
study director · Stemline Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elacestrant

Start the discussion